NO994390L - Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer - Google Patents
Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorerInfo
- Publication number
- NO994390L NO994390L NO994390A NO994390A NO994390L NO 994390 L NO994390 L NO 994390L NO 994390 A NO994390 A NO 994390A NO 994390 A NO994390 A NO 994390A NO 994390 L NO994390 L NO 994390L
- Authority
- NO
- Norway
- Prior art keywords
- benzothepines
- hmg
- combination therapy
- bile acid
- reductase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4066097P | 1997-03-11 | 1997-03-11 | |
PCT/US1998/003792 WO1998040375A2 (en) | 1997-03-11 | 1998-03-10 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO994390D0 NO994390D0 (no) | 1999-09-10 |
NO994390L true NO994390L (no) | 1999-11-04 |
Family
ID=21912237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO994390A NO994390L (no) | 1997-03-11 | 1999-09-10 | Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0971744A2 (zh) |
JP (1) | JP2002500628A (zh) |
CN (1) | CN1255864A (zh) |
AU (1) | AU730024C (zh) |
BG (1) | BG103793A (zh) |
BR (1) | BR9808013A (zh) |
CA (1) | CA2283575A1 (zh) |
HU (1) | HUP0002395A3 (zh) |
IL (1) | IL131872A0 (zh) |
MX (1) | MXPA99008417A (zh) |
NO (1) | NO994390L (zh) |
NZ (1) | NZ337830A (zh) |
PL (1) | PL336415A1 (zh) |
RU (1) | RU2247579C2 (zh) |
SK (1) | SK125099A3 (zh) |
WO (1) | WO1998040375A2 (zh) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US6083497A (en) | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
AU2003241629B2 (en) * | 1999-04-19 | 2005-06-16 | Astrazeneca Ab | An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
AU2001247331A1 (en) * | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
SE0003766D0 (sv) * | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002051396A1 (fr) * | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions pharmaceutiques contenant des derives de cyclobutene |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
MXPA04005864A (es) | 2001-12-19 | 2004-10-29 | Atherogenics Inc | Derivados de charcona y su uso para tratar enfermedades. |
US7202247B2 (en) | 2001-12-19 | 2007-04-10 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
ATE531701T1 (de) * | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CA2557576C (en) | 2004-02-27 | 2010-02-09 | Asahi Kasei Pharma Corporation | Novel benzothiazepine and benzothiepine compounds |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
EP2968262A1 (en) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3197459A4 (en) * | 2014-09-28 | 2018-06-20 | Huahui Health Ltd. | Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
ES2937153T3 (es) | 2019-02-06 | 2023-03-24 | Albireo Ab | Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares |
EP3921027B1 (en) | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
AU2020221834A1 (en) | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
HUE065571T2 (hu) | 2019-12-04 | 2024-06-28 | Albireo Ab | Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként |
CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
CN112274648B (zh) * | 2020-11-23 | 2022-10-14 | 郑州大学 | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
TW202423921A (zh) * | 2022-08-22 | 2024-06-16 | 美商安塔製藥公司 | 稠合的雜雙環抗病毒劑 |
-
1998
- 1998-03-10 PL PL98336415A patent/PL336415A1/xx unknown
- 1998-03-10 MX MXPA99008417A patent/MXPA99008417A/es unknown
- 1998-03-10 NZ NZ337830A patent/NZ337830A/en not_active Application Discontinuation
- 1998-03-10 AU AU64408/98A patent/AU730024C/en not_active Ceased
- 1998-03-10 EP EP98910075A patent/EP0971744A2/en not_active Withdrawn
- 1998-03-10 JP JP53959498A patent/JP2002500628A/ja not_active Abandoned
- 1998-03-10 IL IL13187298A patent/IL131872A0/xx unknown
- 1998-03-10 WO PCT/US1998/003792 patent/WO1998040375A2/en not_active Application Discontinuation
- 1998-03-10 SK SK1250-99A patent/SK125099A3/sk unknown
- 1998-03-10 CA CA002283575A patent/CA2283575A1/en not_active Abandoned
- 1998-03-10 HU HU0002395A patent/HUP0002395A3/hu unknown
- 1998-03-10 BR BR9808013-0A patent/BR9808013A/pt not_active IP Right Cessation
- 1998-03-10 RU RU99121514/15A patent/RU2247579C2/ru not_active IP Right Cessation
- 1998-03-10 CN CN98804995A patent/CN1255864A/zh active Pending
-
1999
- 1999-09-10 NO NO994390A patent/NO994390L/no not_active Application Discontinuation
- 1999-10-11 BG BG103793A patent/BG103793A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0971744A2 (en) | 2000-01-19 |
WO1998040375A2 (en) | 1998-09-17 |
AU730024B2 (en) | 2001-02-22 |
AU730024C (en) | 2004-08-05 |
HUP0002395A3 (en) | 2002-12-28 |
PL336415A1 (en) | 2000-06-19 |
CA2283575A1 (en) | 1998-09-17 |
MXPA99008417A (es) | 2005-02-03 |
RU2247579C2 (ru) | 2005-03-10 |
WO1998040375A3 (en) | 1998-12-03 |
SK125099A3 (en) | 2001-02-12 |
CN1255864A (zh) | 2000-06-07 |
NZ337830A (en) | 2001-07-27 |
BR9808013A (pt) | 2001-09-25 |
IL131872A0 (en) | 2001-03-19 |
HUP0002395A2 (hu) | 2001-05-28 |
BG103793A (en) | 2000-07-31 |
AU6440898A (en) | 1998-09-29 |
NO994390D0 (no) | 1999-09-10 |
JP2002500628A (ja) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO994390L (no) | Kombinasjonsterapi som anvender ileal gallesyretransportinhiberende benzotiepiner og HMG Co-A reduktaseinhibitorer | |
DK1216247T3 (da) | Imidazoimidazoler og triazoler som anti-inflammatoriske midler | |
NO20010016D0 (no) | Benzotiepiner med aktivitet som inhibitorer for ileal gallesyretransport og opptak av taurocholat | |
ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
NO990296D0 (no) | HPPD-genet og inhibitorer | |
NO20001323D0 (no) | Dipeptid-apoptose inhibitorer og deres anvendelse | |
MXPA03003417A (es) | Formulacion oral que comprende un compuesto inhibidor del transporte biliar ileal y un inhibidor de reductasa hmgco-a. | |
DK0944590T3 (da) | Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer | |
GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
NO993956L (no) | Fremgangsmåte for målfölging | |
HUP0100427A3 (en) | Ace inhibitor-mmp inhibitor combinations | |
DK0914124T3 (da) | Antithrombotisk, antiatherosclerotisk, farmaceutisk sammensætning omfattende et thienopyridinderivat og en HMG-CoA-reduktasehæmmer | |
AU9802798A (en) | Gas treating solution corrosion inhibitor | |
AU9197598A (en) | Inducing neurotransmitter and neuropeptide activity | |
AU8673598A (en) | Neuraminidase inhibitors | |
NO20000371D0 (no) | Aminoetylfenoksyeddiksyrederivater og legemidler for smertereduksjon og kalksteinfjerningsfremming i urin litiasis | |
AU9443898A (en) | Wof inhibitor | |
EP1232159A4 (en) | INHIBITORS OF BETA AMYLOID PEPTIDES | |
AU3721000A (en) | Corrosion inhibitor and process | |
HUP0201597A3 (en) | Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines | |
DK199901135A (da) | Fremgangsmåde og indretning til gennemførsel af økonomiske transaktioner | |
NO303034B1 (no) | Kvitteringslapp for kassaapparat og lignende | |
HU9700818D0 (en) | Pharmaceutical ointment against ekzema and psoriasis | |
GB9713709D0 (en) | Inhibitors | |
GB9727371D0 (en) | Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |